Back to today’s briefing

Story perspectives

Hims & Hers Shares Rise Amid Weight-Loss Drug Launch

4/1/2025

37 5

Summary

Story summary

Hims & Hers Health's shares surged 5% following the launch of Eli Lilly's weight-loss drug Zepbound and diabetes treatment Mounjaro on their platform. While Zepbound comes with a hefty price tag of $1,899 per month, the generic liraglutide offers a more affordable option at $299. However, the FDA's resolution of the semaglutide shortage poses challenges for Hims, potentially affecting revenue projections.

1 of 1

Story summary

Hims & Hers Health's shares surged 5% following the launch of Eli Lilly's weight-loss drug Zepbound and diabetes treatment Mounjaro on their platform. While Zepbound comes with a hefty price tag of $1,899 per month, the generic liraglutide offers a more affordable option at $299. However, the FDA's resolution of the semaglutide shortage poses challenges for Hims, potentially affecting revenue projections.